08/02/04

Attorney's Docket No.: 17084-004016/24601-40

ATES PATENT AND TRADEMARK OFFICE IN Th

Gyula Hadlaczky, et. al

Art Unit : 1632

Serial No.: 10/782,129

Examiner: Unknown

Filed

: February 18, 2004

Conf. No.: 5795

Cust. No. : 20985

Title

: ARTIFICIAL CHROMOSOMES, USES THEREOF AND METHODS FOR

PREPARING ARTIFICIAL CHROMOSOMES

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

## Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement and Forms PTO-1449 (2 pages), and cited references for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

 $\bowtie$ 

The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfull subpaitted.

Stephanie L. Seidman

Reg. No. 33,779

Attorney Docket No. 17084-004016/24601-4020

Address all correspondence to:

Stephanie L. Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130

Telephone: (858) 678-5070 Facsimile: (202) 626-7796 email: seidman@fr.com

> CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 399295575 Date of Deposit July 30, 2004

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Traderhark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie L. Seidman

Attorney's Docket No.: 17084-004016/24601-4020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gyula Hadlaczky, et. al

Serial No.: 10/782,129

Filed: February 18, 2004

Art Unit: 1632

Examiner: Unknown

Conf. No.: 5795

Cust. No. : 20985

Title : ARTIFICIAL CHROMOSOMES, USES THEREOF AND METHODS FOR

PREPARING ARTIFICIAL CHROMOSOMES

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed before the receipt of the First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, if it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (2 pages) and copies of the cited references are provided herewith in connection with the above-captioned application.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 399295575

Date of Deposit July 30, 2004

I hereby certify that his paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Papent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie L. Seidman

Applicant: Gyula Hadlaczky, et. al Attorney's Docket No.: 17084-004016/24601-4020

Serial No.: 10/782,129

Filed: February 18, 2004

Supplemental Information Disclosure Statement

Page : 2 of 3

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items are necessary.

Since the last Information Disclosure Statement was filed on May 21, 2004, no additional co-pending applications need be made known to the Examiner.

The Examiner's attention is directed to the cited reference Oberle et al. (Biochimica et Biophysica Acta (2004) 1676:223-230). Oberle et al. describes methods for delivering artificial chromosome expression systems (ACEs) to cells. Specifically, Oberle et al. demonstrates that when cells are treated with ultrasound energy and the cationic lipid SAINT-2 or DOTAP prior to contacting them with ACEs, the ACEs are delivered into the cells. Oberle et al. states that, prior to its publication, there was no suitable procedure for delivering ACEs into cells because the size of the ACEs was too large to allow internalization of ACEs complexed with cationic lipids or polymers (see, e.g., Abstract at page 223 and page 224, col. 1, para. 3). Oberle et al. further states that incubation of ACEs with cationic lipids such as SAINT-2 and DOTAP to prepare ACEs/lipid complexes leads to partial unraveling of the ACEs with a loss of their condensed structure (see page 225, col. 1, para. 2). Oberle et al. does not provide any data to support these statements.

The instant application, as well as in U.S. Patent No. 6,743,967, which is a parent application of the instant application, however, describes the introduction of artificial chromosomes, including ACEs, into cells by lipid-mediated transfection (see, *e.g.*, p. 8, line 15; p. 23, line 26; p. 32, line 12; p. 34, line 15; p. 35, lines 23 and 28; p. 52, line 23, and p. 105, line 23; and p.117, lines 6 and 22 of the instant application).

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(b) exists.

Applicant: Gyula Hadlaczky, et. al Attorney's Docket No.: 17084-004016/24601-402O

Serial No.: 10/782,129

Filed: February 18, 2004

Supplemental Information Disclosure Statement

Page : 3 of 3

\* \* \* \*

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie L. Seidman Reg. No. 33,779

Attorney Docket No. 17084-004016/24601-4020 Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130

Telephone: (858) 678-5070 Facsimile: (202) 626-7796 email: seidman@fr.com

						_	
Substitute For (Modified)	<i>f</i> .	اوانهای©P ا∸یمدی دالل	partment of Commerce t and Trademark Office	Attorney's Docket No. 17084-004016 (24601-402O)		Application No 10/782,129	
List of Patents and Publications for Applicant's Information Disclarate Statement			Applicant				
			Gyula Hadlaczky, et. al				
(37 CFR §1.98(b))				Filing Date		Group Art Unit	
				February 18, 2004		1632	
			U.S. Paten	Documents			
Examiner	Desig.	Document	Publication				Filing Date
Initial	ID	Number	Date	Patentee	Class	Subclass	If Appropriate
	NONE						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	NONE							

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
	AA	Choo, K.H.A., "Turning on the centromere", Nature Genetics 18:3-4 (1998)			
	AB	Eyestone, "Production and breeding of transgenic cattle using in vitro embryo production technology", <i>Theriogeneology 51</i> :509-517 (1999)			
	AC	Fabb et al., "Generation of novel human MHC class II mutant B-cell lines by integrating YAC DAN into a cell line homozygously deleted for the MHC class II region", <i>Human Molecular Genetics</i> 6(8):1295-1304 (1997)			
	AD	Featherstone and Huxley, "Extrachromosomal maintenance and amplification of yeast artificial chromosomes", <i>Genomics</i> 17:267-278 (1993)			
	AE	Financsek <i>et al.</i> , :Human ribosomal RNA gene: Nucleotide sequence of the transcription initiation region and comparison of three mammalian genes", <i>Proc. Natl. Acad. Sci.</i> 79: 3092-3096 (1982)			
	AF	Gonzalez and Schmickel, "The human 18S ribosomal RNA gene: Evolution and stability", Am. J. Hum. Genet. 38: 419-427 (1986)			
	AG	Gonzalez et al., "Variation among human 28S ribosomal RNA genes", Proc. Natl. Acad. Sci. USA 82:7666-7670 (1985)			
	АН	Hoffman et al., "Lipochromosomes mediated gene transfer: identification and probable specificity of localization of human chromosomal material and stability of the transferents", In Vitro 17(8):735-740 (1981)			
	AI	Huxley, "Mammalian artificial chromosomes and chromosome transgenics", <i>Trends in Genetics 13</i> (9):245-147 (1997)			

Examiner Signature	Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in				

Substitute Form PTO-1449
(Modified)

U.S. Department of Commerce Patent and Trademark Office

(Modified)

List of Patents and Publications for Applicant's Information Disclosure Statement

(37 CFR §1.98(b))

Attorney's Docket No. 17084-004016 (24601-4020)

Applicant Gyula Hadlaczky, et. al

Filing Date

Filing Date

Group Art Unit

(37 CFR §1.98(b))			February 18, 2004	1632	
<del></del>	Other D	ocuments (include Author, T			
Examiner	Desig.				
Initial	ID		Document		
	AJ	219 (1982)  McCallum and Maden, "Human 18S ribosomal RNA sequences inferred from DNA sequence," Biochem J. 232:725-733 (1985)  Moreadith et al., "Gene targeting in embryonic stem cells: the new physiology and metabolism", J. Mol. Med. 75:208-216 (1997)  Mukherjee et al., "Entrapmentof metaphase chromosomes into phospholipid vesicles			
	AK				
	AL				
	AM				
	ĄN	Nazar et al., "Sequence homologies in mammalian 5.8S ribosomal RNA", Biochem. 15(3):505-508 (1976)			
	AO Oberle et al., "Efficient transfer of chromosome-based DNA constructs into mammalicells," Biochimica et Biophysica Acta 1676: 223-30 (2004)  Orkin, S.H., Report and Recommendations of the Panel to Assess the NIH Investme Research of Gene Therapy, December 7, 1995, pages 1-45. Available online at:			constructs into mammalian	
		http://www/nih.gov/news/panelrep.h	ntml		
	AQ	Parkman et al., "Abstract for: Gene Rev. Med. 51 33-47 (2000)	Therapy for adenosine of	deaminase deficiency", <i>Annual</i>	
	AR	Safrany and Hidvegi, "New tandem ribosomal RNA gene", <i>Nucl. Acids</i>	repeat region in the non <i>Res. 17</i> (8):3013-3023 (1	-transcribed spacer of human 989)	
	AS	Smith and Rubin, "Functional scree affecting learning in mice", Human	ening and complex traits: Mol. Genet. 6(10):1729-	human 21q22.2 sequences 1733 (1997)	
AT Stubblefield and Pershouse, "Direct forms chromosome transfer", Somatic Cell and			t formation of microcells II and Molec. Genet. 18:4	from mitotic cells for use in 485-491 (1992)	
	AU	Verma and Somia, "Gene Therapy 242 (1997)	– promises, problems ar	nd prospects", Nature 389:239	
	AV	Vile, R.G., "Abstract of: Cancer Ger Therapy 7(1):2-8 (2000)	ne Therapy: Hard Lesson	ns and New Courses", <i>Gene</i>	
	AW	Wells et al., "Production of cloned I comparison between in vivo- and in 57:385-390 (1997)			

Examiner Signature	Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in				
conformance and not considered. Include copy of this form with next communication to applicant.				